Zuber, C., Fan, J.Y., Guhl, B., Parodi, A., Fessler, J.H., Parker, C
N Engl J Med 375(4):311322 Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jdar E, Leiter LA, SUSTAIN-6 Investigators et al (2016b) Semaglutide and cardiovascular outcomes in patients with type 2 diabetes
Suppressive effect erythropoietin on oxidative stress by targeting AMPK/NOX4/ROS pathway in renal ischemia reperfusion injury
Semaglutide mimics this hormone with a longer half-life, making once-weekly dosing possible
Third, additional analyses were performed using alternative comparator definitions, including restriction to semaglutide, to assess the impact of treatment heterogeneity
Haddad R, Decalf V, Monaghan TF, et al